share_log

Insiders At MiMedx Group Sold US$659k Of Stock Potentially Indicating Weakness

Insiders At MiMedx Group Sold US$659k Of Stock Potentially Indicating Weakness

MiMedx集團內部人士出售65.9萬美元的股票,可能表明股價疲軟
Simply Wall St ·  20:45

Despite the fact that MiMedx Group, Inc. (NASDAQ:MDXG) stock rose 17% last week, insiders who sold US$659k worth of stock in the previous 12 months are likely to be better off. Selling at an average price of US$8.02, which is higher than the current price, may have been the best move for these insiders because their investment would have been worth less now than when they sold.

儘管上週MimedX集團公司(納斯達克股票代碼:MDXG)股價上漲了17%,但在過去12個月中出售了價值65.9萬美元股票的內部人士的境況可能會好轉。對於這些內部人士來說,以平均8.02美元(高於當前價格)出售可能是最佳舉動,因爲他們現在的投資價值將低於出售時的價值。

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

儘管我們認爲股東不應該簡單地關注內幕交易,但邏輯要求你應該注意內部人士是在買入還是賣出股票。

The Last 12 Months Of Insider Transactions At MiMedx Group

MimedX 集團過去 12 個月的內幕交易

The insider, Ricci Whitlow, made the biggest insider sale in the last 12 months. That single transaction was for US$250k worth of shares at a price of US$8.06 each. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (US$6.85). So it may not tell us anything about how insiders feel about the current share price.

知情人裏奇·惠特洛進行了過去12個月中最大規模的內幕出售。這筆單筆交易是價值25萬美元的股票,每股價格爲8.06美元。儘管內幕拋售是負面的,但對我們來說,如果以較低的價格出售股票,則負面影響更大。一線希望是,這次拋售發生在最新價格(6.85美元)上方。因此,它可能無法告訴我們內部人士對當前股價的看法。

All up, insiders sold more shares in MiMedx Group than they bought, over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

總而言之,在過去的一年中,內部人士出售的MimeDx集團股票比他們買入的還要多。下圖顯示了去年的內幕交易(公司和個人)。如果你點擊圖表,你可以看到所有的個人交易,包括股價、個人和日期!

big
NasdaqCM:MDXG Insider Trading Volume November 1st 2024
納斯達克股票代碼:MDXG 內幕交易量:2024 年 11 月 1 日

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找隱藏寶石的人來說,這份最近有內幕收購的小盤股公司的免費清單可能就是門票。

Insider Ownership Of MiMedx Group

MimeDx 集團的內部所有權

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 1.4% of MiMedx Group shares, worth about US$14m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

許多投資者喜歡查看公司內部人士擁有多少股份。我認爲,如果內部人士擁有該公司的大量股份,這是一個好兆頭。內部人士擁有MimedX集團1.4%的股份,價值約1400萬美元。這種內部所有權水平不錯,但還沒有特別突出。這無疑表明了一定程度的一致性。

So What Does This Data Suggest About MiMedx Group Insiders?

那麼這些數據對MimedX集團內部人士有什麼啓示呢?

The fact that there have been no MiMedx Group insider transactions recently certainly doesn't bother us. We don't take much encouragement from the transactions by MiMedx Group insiders. But it's good to see that insiders own shares in the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing MiMedx Group. For instance, we've identified 3 warning signs for MiMedx Group (2 shouldn't be ignored) you should be aware of.

最近沒有MimedX集團的內幕交易這一事實肯定不會打擾我們。我們並沒有從MimeDx集團內部人士的交易中得到太多鼓勵。但很高興看到內部人士擁有該公司的股份。除了了解正在進行的內幕交易外,確定MimeDx集團面臨的風險也是有益的。例如,我們已經確定了 MimeDx 集團的 3 個警告信號(2 個不容忽視),你應該注意。

Of course MiMedx Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

當然,MimedX集團可能不是最值得購買的股票。因此,您可能希望看到這個免費的高質量公司集合。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論